Prospective randomized study of effects of unopposed estrogen replacement therapy on markers of coagulation and inflammation in postmenopausal women

Journal of Clinical Endocrinology and Metabolism

Volumn 86, Issue 8, 2001, Pages 3629-3634

  Luyer, M D P ^a   Khosla, S ^a   Owen, W G ^a   Miller, V M ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; C REACTIVE PROTEIN; CONJUGATED ESTROGEN; ESTROGEN; LIPID; LOW DENSITY LIPOPROTEIN; PADGEM PROTEIN; PLACEBO; PLASMINOGEN; PROTHROMBIN; TISSUE FACTOR PATHWAY INHIBITOR;

AGED; ARTICLE; BLOOD CLOTTING; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ESTROGEN THERAPY; FEMALE; HUMAN; INFLAMMATION; LIPID BLOOD LEVEL; POSTMENOPAUSE; PRIORITY JOURNAL; RISK FACTOR; THROMBOSIS; TREATMENT PLANNING; VEIN THROMBOSIS;

EID: 0034885985     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.86.8.7768     Document Type: Article

References (43)

1. Hormones and vasoprotection
2. Hormone and nonhormone therapy for the maintenance of postmenopausal health: The need for randomized controlled trials of estrogen and Raloxifene
3. Postmenopausal estrogen therapy and cardiovascular disease: Ten-year follow-up from the Nurses' Health Study
4. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
5. Risk of venous thromboembolism in users of hormone replacement therapy
6. Mortality and morbidity in transsexual subjects treated with cross-sex hormones
7. Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: Flutamide versus diethylstilbestrol
8. Hormone replacement therapy, inflammation, and hemostasis in elderly women
9. Hormone replacement therapy and increased plasma concentration of C-reactive protein
10. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: A randomized, controlled trial
11. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
12. Mechanisms of disease: Acute-phase proteins and other systemic responses to inflammation
13. Neutrophils and deep venous thrombosis
14. Effects of hormone replacement therapies on fibrinogen and plasma viscosity in postmenopausal women
15. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women: A randomized controlled trial
16. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women
17. Effects of hormone replacement therapy on the circadian pattern of atherothrombotic risk factors
18. Relation of fibrinolytic potentiation by estrogen to coagulation pathway activation in postmenopausal women
19. Fibrinogen and plasminogen modifications during oral estradiol replacement therapy
20. Hormone replacement therapy improves cardiovascular risk by lowering plasma viscosity in postmenopausal women
21. Decreased plasma tissue factor pathway inhibitor in women taking combined oral contraceptives
22. Effects of hormone-replacement therapy on hemostatic factors, lipid factors, and endothelial function in women undergoing surgical menopause: Implications for prevention of atherosclerosis
23. Transdermal estrogen replacement therapy: Beneficial effects on hemostatic risk factors for cardiovascular disease
24. Prospective study of exogenous hormones and risk of pulmonary embolism in women
25. Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study
26. Thrombosis and hormone replacement therapy in postmenopausal women
27. Effect of estrogen-progestin hormonal replacement therapy on plasma antithrombin III of postmenopausal women
28. Studies of a mechanism inhibiting the initiation of the extrinsic pathway of coagulation
29. Extrinsic pathway inhibitor: The key to feedback control of blood coagulation initiated by tissue thromboplastin
30. Determination of vitamin K sensitive coagulation factors in plasma. Studies on three methods using synthetic chromogenic substrates
31. Methods for determination of plasmin, antiplasmin and plasminogen by means of substrate S-2251
32. Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay
33. Preparation and properties of serum and plasma proteins. XV. Some factors influencing the quantitative determination of fibrinogen
34. Effect of removal of the liver on blood coagulation
35. Robust tests for the equality of variances
36. A note on normal correlation
37. The menopause and hormone replacement therapy: Lipids, lipoproteins, coagulation and fibrinolytic factors
38. Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women
39. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women
40. Distribution and correlates of plasma fibrinogen in middle-aged women: Initial findings of the Postmenopausal Estrogen/Progestin Interventions (PEPI) study
41. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/Progestin Replacement Study
42. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in elderly subjects
43. Effect of postmenopausal hormones on inflammation-sensitive proteins